Silence Therapeutics reported Phase 2 success for its siRNA therapy divesiran in polycythemia vera, hitting the trial’s primary endpoint in the 48-person study. Silence said 88% of patients receiving divesiran achieved a clinical response versus 19% on placebo. The data position divesiran to move into Phase 3 as Silence seeks to compete for a role in the PV treatment landscape and challenge upcoming products by improving red blood cell control with RNA interference technology. The company highlighted the response rate and set up a potential late-stage pivot toward commercialization timelines. If confirmed in larger datasets, the outcome could raise competitive pressure in rare blood cancers where efficacy, safety, and durability of response determine adoption. For clinicians and developers, the readout also adds another data point to the growing siRNA pipeline maturation cycle.